Bradley J. Carver
Director Ejecutivo en SynDevRx, Inc. .
Perfil
Bradley J.
Carver is the founder of SynDevRx, Inc. Prior to that, he served as the President, Chief Executive Officer, and Treasurer of Glycogenesys, Inc. from 1995 to 2006.
He obtained his undergraduate degree from Michigan State University in 1983.
Cargos activos de Bradley J. Carver
Empresas | Cargo | Inicio |
---|---|---|
SynDevRx, Inc.
SynDevRx, Inc. Miscellaneous Commercial ServicesCommercial Services SynDevRx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA. | Director Ejecutivo | - |
Antiguos cargos conocidos de Bradley J. Carver.
Empresas | Cargo | Fin |
---|---|---|
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Presidente | 31/01/2006 |
Formación de Bradley J. Carver.
Michigan State University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
SynDevRx, Inc.
SynDevRx, Inc. Miscellaneous Commercial ServicesCommercial Services SynDevRx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA. | Commercial Services |
- Bolsa de valores
- Insiders
- Bradley J. Carver